Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells have been recently described to localize to breast carcinomas, where they integrate into the tumour-associated stroma. However, the involvement of mesenchymal stem cells (or their derivatives) in tumour pathophysiology has not been addressed. Here, we demonstrate that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft. The breast cancer cells stimulate de novo secretion of the chemokine CCL5 (also called RANTES) from mesenchymal stem cells, which then acts in a paracrine fashion on the cancer cells to enhance their motility, invasion and metastasis. This enhanced metastatic ability is reversible and is dependent on CCL5 signalling through the chemokine receptor CCR5. Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MSC can be mobilized and recruited to active tumor sites, where they can incorporate into the tumor’s microenvironment [5, 68, 100–103].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“CCL5 can be secreted by both BM-MSC and ASC [100, 144] and displays pro-proliferative activities on breast cancer cell lines [145, 146].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“Another MSC-secreted pro-metastasis cytokine, CCL5 (RANTES), can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers [73, 87, 100, 142–144].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“The injection of bone marrow-derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [40]
In the citing paper
“CAFs comprise the majority of cell types within the TME, and their reciprocal interactions with cancer cells have been well documented (Whiteside, 2008; Hazlehurst et al., 2003; Karnoub et al., 2007).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Karnoub et al., 2007
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Self-citationCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citationCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Self-citationHuman Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
(2002) · PubMed · Cited by 903
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Self-citation
Cited by
Items 801–900 of 1,024
Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
Chen, D., Lu, D., Lin, H., & Yeh, W. (2014) · BioMed Research International · doi:10.1155/2014/532161 · Cited by 91
Stem cell-based therapy for malignant glioma
Bexell, D., Svensson, A., & Bengzon, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.006 · Cited by 85
Vallabhaneni, K. C., Hassler, M.-Y., Abraham, A., Whitt, J., Mo, Y.-Y., Atfi, A., & Pochampally, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166027 · Cited by 87
Honoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90
Shojaei, S., Hashemi, S. M., Ghanbarian, H., Salehi, M., & Mohammadi‐Yeganeh, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27326 · Cited by 84
“CCL5 increased extravasation of cancer cell and promoted tumor cell metastasis (Karnoub et al., 2007).”
BackgroundCrean, D., & Murphy, E. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.589770 · Cited by 90
“The molecular mechanisms behind this movement are still not fully elucidated but are becoming more recognized as important, owing to the fact that MSCs within the TME are often linked with poorer prognosis, augmenting angiogenesis, tumor formation, and metastasis (Karnoub et al., 2007).”
BackgroundStrelez, C., Chilakala, S., Ghaffarian, K., Lau, R., Spiller, E. R., Ung, N. M., Hixon, D., Yoon, A. Y., Sun, R., Lenz, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102509 · Cited by 92
Peyraud, F., Guégan, J., Rey, C., Lara, O., Odin, O., Castillo, M. D., Vanhersecke, L., Coindre, J., Clot, E., Brunet, M., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101934 · Cited by 91
Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases
Cook, L. M., Shay, G., Aruajo, A., & Lynch, C. C. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9494-4 · Cited by 90
Park, S. Y., Kim, H. M., & Koo, J. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3291-9 · Cited by 91
“The most important and best studied elements of tumor microenvironments are cancer-associated fibroblasts (CAF) [1–3], which surround cancer cells and are related to tumor initiation [4], tumor-stimulatory inflammation [5], metabolism [6], metastasis [7], drug response [8], and immune surveillance [9].”
Yamada, K., Uchiyama, A., Uehara, A., Perera, B., Ogino, S., Yokoyama, Y., Takeuchi, Y., Udey, M. C., Ishikawa, O., & Motegi, S.-I. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2812 · Cited by 87
“In addition, several studies have reported that MSC can differentiate into fibroblasts, myofibroblasts or pericyte-like cells and enhance angiogenesis, resulting in tumor progression and metastasis in vivo (10-14).”
A Zebrafish Model Discovers a Novel Mechanism of Stromal Fibroblast-Mediated Cancer Metastasis
Liu, C., Zhang, Y., Lim, S., Hosaka, K., Yang, Y., Pavlova, T. V., Alkasalias, T., Hartman, J., Jensen, L. D., Xing, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0101 · Cited by 90
“It is known that CCL5 mediates breast cancer metastasis through a tumor stromal mechanism (37).”
BackgroundRole of Apelin/APJ axis in cancer development and progression
Masoumi, J., Jafarzadeh, A., Khorramdelazad, H., Abbasloui, M., Abdolalizadeh, J., & Jamali, N. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.02.002 · Cited by 89
Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
Bagley (2009) · International Journal of Oncology · doi:10.3892/ijo_00000187 · Cited by 89
Behavior of immune players in the tumor microenvironment
Pittet, M. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bc38a · Cited by 83
Characterization and Regulation of Bv8 in Human Blood Cells
Zhong, C., Qu, X., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1954 · Cited by 89
Takigawa, H., Kitadai, Y., Shinagawa, K., Yuge, R., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2017) · Neoplasia · doi:10.1016/j.neo.2017.02.010 · Cited by 89
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis
Yu, P. F., Huang, Y., Xu, C. L., Lin, L. Y., Han, Y. Y., Sun, W. H., Hu, G. H., Rabson, A. B., Wang, Y., & Shi, Y. F. (2017) · Oncogene · doi:10.1038/onc.2016.252 · Cited by 88
Barreca, M. M., Cancemi, P., & Geraci, F. (2020) · Cells · doi:10.3390/cells9051163 · Cited by 88
Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways
Wang, H., Pan, J., Barsky, L., Jacob, J. C., Zheng, Y., Gao, C., Wang, S., Zhu, W., Sun, H., Lu, L., et al. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00022-z · Cited by 88
Ahmed, A. U., Rolle, C. E., Tyler, M. A., Han, Y., Sengupta, S., Wainwright, D. A., Balyasnikova, I. V., Ulasov, I. V., & Lesniak, M. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.131 · Cited by 88
Horie, M., Saito, A., Mikami, Y., Ohshima, M., Morishita, Y., Nakajima, J., Kohyama, T., & Nagase, T. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.104 · Cited by 88
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Onoyama, M., Ohnishi, M., Ohara, E., Higashi, Y., Tanaka, S., Yasui, W., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27735 · Cited by 79
Busuttil, R. A., George, J., Tothill, R. W., Ioculano, K., Kowalczyk, A., Mitchell, C., Lade, S., Tan, P., Haviv, I., & Boussioutas, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3049 · Cited by 77
“In models of breast cancer, it was found that the stromal components derived from mesenchymal stem cells play an important role in divesting metastatic properties to the primary cancer (49).”
BackgroundSkolekova, S., Matuskova, M., Bohac, M., Toro, L., Durinikova, E., Tyciakova, S., Demkova, L., Gursky, J., & Kucerova, L. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0127-0 · Cited by 82
“The MSC within the tumor microenvironment are exposed to the treatment concomitantly with the tumor cells [10] and although the chemoresistance of the MSC was described previously [15, 16], the stress response to the chemotherapy was not characterized in detail.”
BackgroundSong, J., Miermont, A., Lim, C. T., & Kamm, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-36381-5 · Cited by 87
Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction
Kudo‐Saito, C., Fuwa, T., Murakami, K., & Kawakami, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1364 · Cited by 87
“Tumor metastasispromoting activity of MSCs has been already shown using xenograft model implanted with human breast cancer cells and human bone marrow-derived MSCs, and CCL5 has been shown as a molecule essential for the activity (15).”
Yu, Y., Chen, M., Guo, Q., Shen, L., Liu, X., Pan, J., Zhang, Y., Xu, T., Zhang, D., & Wei, G. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00425-0 · Cited by 87
“limitations in clinical application due to potential immune rejection, tumor formation risk, and other aspects [21, 22].”
BackgroundChu, Y., Tang, H., Guo, Y. P., Guo, J., Huang, B., Fang, F., Cai, J., & Wang, Z. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.07.020 · Cited by 89
Kayamori, K., Sakamoto, K., Nakashima, T., Takayanagi, H., Morita, K., Omura, K., Nguyen, S. T., Miki, Y., Iimura, T., Himeno, A., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090299 · Cited by 87
“These cells and their products play crucial roles in establishing the tumor microenvironment, which regulates the proliferation, survival, invasion, and metastasis of the cancer cells.(29,30) We investigated histopathologically 97 cases of OSCCs with bone invasion and demonstrated the significant role of fibrous strom…”
BackgroundAdipose progenitor cells increase fibronectin matrix strain and unfolding in breast tumors
Chandler, E. M., Saunders, M. P., Yoon, C. J., Gourdon, D., & Fischbach, C. (2011) · Physical Biology · doi:10.1088/1478-3975/8/1/015008 · Cited by 76
“While most studies have focused on bone marrow-derived mesenchymal stem cells (Karnoub et al 2007), relatively little is known about the role of adipose tissue-derived mesenchymal stem cells (i.e. ASCs) in the tumor microenvironment.”
BackgroundBoth human and mouse mesenchymal stem cells promote breast cancer metastasis
Albarenque, S. M., Zwacka, R. M., & Mohr, A. (2011) · Stem Cell Research · doi:10.1016/j.scr.2011.05.002 · Cited by 87
“(Karnoub et al., 2007) have reported that human MSCs promote the development of metastasis in a human breast cancer model.”
BackgroundSTAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
Yi, E. H., Lee, C. S., Lee, J., Lee, Y. J., Shin, M. K., Cho, C., Kang, K. W., Lee, S. E., Han, W., Noh, D., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0217 · Cited by 88
“This observation was in agreement with previous reports that RANTES activates STAT3 signaling in breast cancer cells (38, 39).”
ResultAlba-Castellón, L., Olivera-Salguero, R., Mestre-Farrera, A., Peña, R., Herrera, M., Bonilla, F., Casal, J. I., Baulida, J., Peña, C., & García de Herreros, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0176 · Cited by 78
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194719 · Cited by 72
Gallo, M., Luca, A. D., Lamura, L., & Normanno, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr159 · Cited by 86
“[14] demonstrated that MSCs cause weakly metastatic breast cancer cells to acquire enhanced metastatic abilities through the secretion of RANTES.”
BackgroundResultInfluentialZhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85
Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis
Mao, L., Yang, J., Yue, J., Chen, Y., Zhou, H., Fan, D., Zhang, Q., Buraschi, S., Iozzo, R. V., & Bi, X. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.10.001 · Cited by 86
Cytokines driving breast cancer stemness
Chin, A. R., & Wang, S. E. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.024 · Cited by 85
“Bone marrow-derived MSCs can be recruited to the sites of breast tumors and increase the metastatic potency of tumor cells (Karnoub et al., 2007).”
Inflammation-Induced Hepatocellular Carcinoma Is Dependent on Ccr5 in Mice
Barashi, N., Weiss, I. D., Wald, O., Wald, H., Beider, K., Abraham, M., Klein, S., Goldenberg, D., Axelrod, J., Pikarsky, E., et al. (2013) · Hepatology · doi:10.1002/hep.26403 · Cited by 77
Sasaki, S., Baba, T., Nishimura, T., Hayakawa, Y., Hashimoto, S., Gotoh, N., & Mukaida, N. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.005 · Cited by 85
Thomas, J. K., Mir, H., Kapur, N., Bae, S., & Singh, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40514-9 · Cited by 85
Dynamic roles of inflammasomes in inflammatory tumor microenvironment
Jang, J., Kim, D., & Surh, Y. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00154-7 · Cited by 86
Sun (2009) · Oncology Reports · doi:10.3892/or_00000331 · Cited by 84
“The metastasis of cancer consisting of a series of complex steps is influenced and regulated by various factors in the microenvironment (2-5).”
Therapeutic Implications of Mesenchymal Stem Cells in Liver Injury
Puglisi, M. A., Tesori, V., Lattanzi, W., Piscaglia, A. C., Gasbarrini, G. B., D′Ugo, D. M., & Gasbarrini, A. (2011) · BioMed Research International · doi:10.1155/2011/860578 · Cited by 81
“Several evidences suggest that MSCs might promote tumor growth via transformation, suppression of the antitumor immune response, and direct trophic action on tumor cells [77–86].”
BackgroundGlutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion
Mestre‐Farrera, A., Bruch‐Oms, M., Peña, R., Rodríguez-Morató, J., Alba‐Castellón, L., Comerma, L., Quintela-Fandiño, M., Duñach, M., Baulida, J., Pozo, Ó. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0622 · Cited by 84
“We extended our study to other epithelial tumor cells and mesenchymal cells, such as MSCs, because these cells contribute to the formation ofCAFs (4, 24, 25).”
BackgroundConditioned mesenchymal stem cells produce pleiotropic gut trophic factors
Watanabe, S., Arimura, Y., Nagaishi, K., Isshiki, H., Onodera, K., Nasuno, M., Yamashita, K., Idogawa, M., Naishiro, Y., Murata, M., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0901-3 · Cited by 85
Ko, Y., Domingo‐Vidal, M., Roche, M. E., Lin, Z., Whitaker‐Menezes, D., Seifert, E. L., Capparelli, C., Tuluc, M., Birbe, R., Tassone, P. T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740209 · Cited by 84
“Fibroblasts have been shown to promote breast cancer tumor growth (4) and metastasis (5).”
Background3D Microfluidic Bone Tumor Microenvironment Comprised of Hydroxyapatite/Fibrin Composite
Ahn, J., Lim, J., Jusoh, N., Lee, J., Park, T.-E., Kim, Y., Kim, J., & Jeon, N. L. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00168 · Cited by 81
“In addition, studies involving coinjection of tumor cells and mesenchymal cells from different sources have demonstrated the importance of stromal fibroblasts for tumor initiation, growth, and metastasis (Camps et al., 1990; Karnoub et al., 2007).”
BackgroundSai, B., Dai, Y., Fan, S., Wang, F., Wang, L., Li, Z., Tang, J., Wang, L., Zhang, X., Zheng, L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2149-1 · Cited by 84
Bian, Z., Fan, Q., Li, G., Xu, W., & Tang, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01731.x · Cited by 83
Review of Mesenchymal Stem Cells and Tumors: Executioner or Coconspirator?
Feng, B., & Chen, L. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0652 · Cited by 83
“27 MSCs could also facilitate low-invasive breast cancer cells (MCF7 and T47D) to entry across the blood vessels into bone marrow in an early period when the tumor burden was low, partly through Tac1-mediated regulation of CXCL12 (SDF-1 a ) and its receptor, CXCR4.”
Akiyoshi, S., Fukagawa, T., Ueo, H., Ishibashi, M., Takahashi, Y., Fabbri, M., Sasako, M., Maehara, Y., Mimori, K., & Mori, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.326 · Cited by 83
“Since Karnoub et al (2007) reported the role of microRNAs in breast cancer metastasis, several studies have investigated whether microRNAs are regulators of the metastatic process.”
BackgroundHuman mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts
Pacioni, S., D’Alessandris, Q. G., Giannetti, S., Morgante, L., Coccè, V., Bonomi, A., Buccarelli, M., Pascucci, L., Alessandri, G., Pessina, A., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0516-3 · Cited by 78
“Such a dual role of MSCs on cancer biology has been widely addressed in literature [29], where both protumorigenic [30, 31] and counter-tumorigenic effects are reported [9–16, 32].”
BackgroundPotential of Mesenchymal Stem Cell based application in Cancer.
Ramdasi, S., Sarang, S. A., & Viswanathan, C. (2015) · PubMed Central · Cited by 83
Roger, M., Clavreul, A., Venier‐Julienne, M., Passirani, C., Montero‐Menei, C. N., & Meneï, P. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.056 · Cited by 83
Xu, Q., Wang, L., Li, H., Han, Q., LI, J., Qu, X., HUANG, S. H., & Zhao, R. C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1541 · Cited by 83
“Accumulating evidence suggests that the interactions between MSCs and breast cancer cells may impact the phenotype of the cancer cells and promote their metastatic potential (19-22).”
BackgroundPaino, F., La Noce, M., Di Nucci, D., Nicoletti, G. F., Salzillo, R., De Rosa, A., Ferraro, G. A., Papaccio, G., Desiderio, V., & Tirino, V. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.308 · Cited by 79
Bott, A., Erdem, N., Lerrer, S., Hotz‐Wagenblatt, A., Breunig, C., Abnaof, K., Wörner, A., Wilhelm, H., Münstermann, E., Ben‐Baruch, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14915 · Cited by 83
“At last, MSC-released CCL5 has been linked to invasion of cancer cells and lung metastasis formation [17, 45].”
BackgroundGera, R., Chehade, H. E. H., Wazir, U., Tayeh, S., Kasem, A., & Mokbel, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-59908-1 · Cited by 83
Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
Pasquet, M., Golzio, M., Mery, E., Rafii, A., Benabbou, N., Mirshahi, P., Hennebelle, I., Bourin, P., Allal, B., Teissie, J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24886 · Cited by 82
“showed that MSC, through paracrine signals such as chemokine (CC motive) ligand 5 (CCL5), enhances the metastatic ability of tumor cells.(15) However, the role of these bone marrow-derived MSC in oncogenesis remains controversial because several authors have in contrast reported an inhibitory effect of MSC on tumor gr…”
BackgroundMele, V., Muraro, M. G., Calabrese, D., Pfaff, D., Amatruda, N., Amicarella, F., Kvinlaug, B., Bocelli‐Tyndall, C., Martin, I., Resink, T. J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28598 · Cited by 71
“On the other hand, MSC-tumor cell crosstalk has been demonstrated to result in de novo secretion of cytokine/chemokines increasing motility, tumorigenicity and metastatic capacity of tumor cells.(11,22) In addition, upon differentiation into cancer-associated fibroblasts,(23,24) MSC may create a stromal niche sustaini…”
BackgroundKim, N., Im, K.-I., Lim, J.-Y., Jeon, E.-J., Nam, Y.-S., Kim, E., & Cho, S. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1796-z · Cited by 82
Hughes, R. M., Simons, B. W., Khan, H., Miller, R., Kugler, V., Torquato, S., Theodros, D., Haffner, M. C., Lotan, T., Huang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2931 · Cited by 75
Stadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 82
Knoop, K., Schwenk, N., Schmohl, K., Müller, A., Zach, C., Cyran, C., Carlsen, J., Böning, G., Bartenstein, P., Göke, B., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146662 · Cited by 73
“In the course of differentiation into CAFs, MSCs induce expression of the chemokine RANTES (11,12).”
BackgroundSwamydas, M., Ricci, K., Rego, S. L., & Dréau, D. (2013) · Cell Adhesion & Migration · doi:10.4161/cam.25138 · Cited by 82
“Indeed, mammary carcinoma co-implanted with mesenchymal stem cells in immune compromised mice led to significant increase in metastatic lesions.(14,16) Stroma cell including mesenchymal stem cells and tumor cell interactions through cell-to-cell contacts or soluble mediators control most aspects of tumor formation and…”
BackgroundResultInfluentialRole of mesenchymal stromal cells in solid organ transplantation
Hematti, P. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2008.05.002 · Cited by 82
“Karnoub et al showed in a murine xenograft model that BM-derived human MSCs, when mixed with otherwise weakly metastatic human breast carcinoma cells and injected into a subcutaneous site, cause cancer cells to greatly increase their metastatic potency [146].”
BackgroundWang, D., & Jang, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1976 · Cited by 82
“(hMSC) within tumor stroma have been shown to secrete the chemokine CCL5 to promote breast cancer metastasis (5).”
BackgroundWang, J., Tham, D., Wei, W., Shin, Y. S., Ma, C., Ahmad, H. M. N., Shi, Q., Yu, J.-K., Levine, R. D., & Heath, J. R. (2012) · Nano Letters · doi:10.1021/nl302748q · Cited by 82
Escobar, P., Bouclier, C., Serret, J., Bièche, I., Brigitte, M., Caicedo, A., Sanchez, E., Vacher, S., Vignais, M., Bourin, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4732 · Cited by 82
“Indeed, cancer cells as well as cells of the tumor microenvironment such as macrophages can increase the motility of MSCs through chemokine production and, on the other hand, MSCs can produce chemokines which increases cancer cell metastasis [9, 13, 30-35].”
BackgroundInfluentialRoles of Metalloproteases in Metastatic Niche
Rucci, N., Sanità, P., & Angelucci, A. (2011) · Current Molecular Medicine · doi:10.2174/156652411797536705 · Cited by 82
“Moreover, in some murine models the process of metastatization is strictly dependent on the presence of active stromal cells [51].”
BackgroundCell therapy for severe burn wound healing
Li, Z., & Maitz, P. (2018) · Burns & Trauma · doi:10.1186/s41038-018-0117-0 · Cited by 82
A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer
Zhang, T., Li, J., He, Y., Yang, F., Hao, Y., Jin, W., Wu, J., Sun, Z., Li, Y., Chen, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06179-0 · Cited by 82
Mesenchymal Stromal Cell Migration: Possibilities to Improve Cellular Therapy
Maijenburg, M. W., van der Schoot, C. E., & Voermans, C. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0270 · Cited by 81
“In animal models, real time tracking of MSC after infusion is often dependent on fluorescent dyes and proteins [74,78] or on reporter constructs that integrate into the genome [79,80].”
Evidence of two distinct functionally specialized fibroblast lineages in breast stroma
Morsing, M., Klitgaard, M. C., Jafari, A., Villadsen, R., Kassem, M. S., Petersen, O. W., & Rønnov‐Jessen, L. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0769-2 · Cited by 81
“A possible overlap among the 302 differentially expressed genes with previously published profiles of breast tumor versus normal stroma was analyzed using Oncomi-ne.org., and tested for significance by Fisher ’ s exact test if common between at least two out of three studies [13 – 15].”
MethodResultMolecular insights into tumour metastasis: tracing the dominant events
Jin, K., Li, T., van Dam, H., Zhou, F., & Zhang, L. (2017) · The Journal of Pathology · doi:10.1002/path.4871 · Cited by 83
“Wnt2 enriched in CTCs or overexpression of signal transducer and activator of transcription 3 (STAT3) suppresses the anoikis of pancreatic cancer cells [48,49].”
BackgroundInfluentialXue, B., Chuang, C.-H., Prosser, H. M., Fuziwara, C. S., Chan, C., Sahasrabudhe, N. S., Kühn, M., Wu, Y., Chen, J., Biton, A., et al. (2021) · Genes & Development · doi:10.1101/gad.347344.120 · Cited by 82
“4I), all of which have been reported to contribute to metastatic potential in different cancer models including lung adenocarcinoma (Ao et al. 2007; Karnoub et al. 2007; Borczuk et al. 2008; Kojima et al. 2010; Straussman et al. 2012; Yu et al. 2015; Sun et al. 2017).”
BackgroundThree-Dimensional 3D Culture Models in Gynecological and Breast Cancer Research
Salinas-Vera, Y. M., Valdés, J., Pérez‐Navarro, Y., Mandujano-Lázaro, G., Marchat, L. A., Ramos‐Payán, R., Núñez-Olvera, S. I., Pérez‐Plasencia, C., & López‐Camarillo, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.826113 · Cited by 81
Jahangiri, B., Khalaj‐Kondori, M., Asadollahi, E., Dizaj, L. P., & Sadeghizadeh, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122214 · Cited by 81
Pacioni, S., D’Alessandris, Q. G., Giannetti, S., Morgante, L., Pascalis, I. D., Coccè, V., Bonomi, A., Pascucci, L., Alessandri, G., Pessina, A., et al. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0185-z · Cited by 81
“on tumor cells [27–29].”
Honda, M., Hori, Y., Nakada, A., Uji, M., Nishizawa, Y., Yamamoto, K., Kobayashi, T., Shimada, H., Kida, N., Satō, T., et al. (2011) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2010.11.008 · Cited by 81
Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Khalid, A., Wolfram, J., Ferrari, I., Mu, C., Mai, J., Yang, Z., Zhao, Y., Ferrari, M., Ma, X., & Shen, H. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955751513150923094709 · Cited by 81
“In a study where breast cancer cells were made to overexpress CCL5, it was found that the chemokine enhances metastasis by increasing the motility and extravasation of cancer cells from the blood to a distant site in the body [25].”
BackgroundInfluentialLelek, J., & Zuba‐Surma, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030799 · Cited by 81
“However, MSC-based therapies may also be accompanied with some risk factors such as cell rejection, undesired immune response, toxicity [11], tumorigenic potential [12,13], prospective contamination with viruses [14], and problematic transport and storage of cells prior to transplantation [15–17].”
BackgroundThe CCL5/CCR5 axis promotes metastasis in basal breast cancer
Velasco-Velázquez, M., & Pestell, R. G. (2013) · OncoImmunology · doi:10.4161/onci.23660 · Cited by 74
“Our results are in agreement with previous findings demonstrating that the CCL5/CCR5 signaling axis plays a crucial role in the metastatic cascade as it is involved in cancer cell extravasation.(10) Blocking the homing of cancer cells to metastatic sites is a highly desirable feature for a bona fide anti-metastatic dr…”
ResultLiu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 80
Wu, C., Dong, S., Huang, R., & Chen, X. (2023) · Cancers · doi:10.3390/cancers15030726 · Cited by 80
“CCL5 is an important chemokine that is primarily secreted by tumor stromal cells under the stimulation of BC cells, and it is closely associated with the invasiveness and metastasis of BC [64,65].”
Muramatsu, S., Tanaka, S., Mogushi, K., Adikrisna, R., Aihara, A., Ban, D., Ochiai, T., Irie, T., Kudo, A., Nakamura, N., et al. (2013) · Hepatology · doi:10.1002/hep.26345 · Cited by 80
“Inflammatory mediators and cells are indispensable components of tumor-host interactions,(30) and studies have shown that cancer cellsecreted factors generate an inflammatory niche hospitable for progression and metastasis of cancer.(31,32) More recent studies have shown that glioma-initiating cells produced inflammat…”
BackgroundRazmkhah, M., Jaberipour, M., Hosseini, A., Safaei, A., Khalatbari, B., & Ghaderi, A. A. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.07.006 · Cited by 80
Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?
Bouffi, C., Djouad, F., Mathieu, M., Noel, D., & Jorgensen, C. (2009) · Rheumatology · doi:10.1093/rheumatology/kep162 · Cited by 70
SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations
Mateo, F., Meca‐Cortés, Ó., Celià-Terrassa, T., Fernández, Y., Abasolo, I., Sánchez‐Cid, L., Bermudo, R., Sagasta, A., Rodríguez‐Carunchio, L., Pons, M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-237 · Cited by 80
“Neoplastic cell subpopulations can interact with nonneoplastic elements of the tumor microenvironment and use them for their advantage [4].”
BackgroundMesenchymal stem cells as a vector for the inflammatory prostate microenvironment
Brennen, W. N., Denmeade, S. R., & Isaacs, J. T. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0151 · Cited by 80
“R e la te d C a n ce r (Karnoub et al. 2007, Klopp et al. 2011), in addition to promoting a pro-tumorigenic environment in the bone marrow (Bergfeld & DeClerck 2010).”
Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells
Bieback, K., Kinzebach, S., & Karagianni, M. (2010) · Stem Cells International · doi:10.4061/2010/193519 · Cited by 80
“Finally, although therapeutically intended in some clinical settings, for example, to prevent or treat GvHD, the immunomodulatory capacities may also favour tumor growth or formation of metastasis, as observed in animal models [76–79].”
BackgroundDoxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use
Baxter-Holland, M., & Dass, C. R. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12869 · Cited by 80
“Building upon these findings, a study by Karnoub et al.([58]) showed that the combination of MCSs with weakly metastatic human breast carcinoma cells led to a significant increase in the cells’ metastatic potential when the cells formed a xenograft.”
ResultFontanella, R., Pelagalli, A., Nardelli, A., D'Alterio, C., Ieranò, C., Cerchia, L., Lucarelli, E., Scala, S., & Zannetti, A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.018 · Cited by 79
Wiest, E. F., & Zubair, A. C. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.040 · Cited by 79
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V., & Ahmadi, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01836-9 · Cited by 70
“Additionally, MSCs release chemokines, such as CXCR4 [30], CCL5, intracellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) [31, 32].”
BackgroundWang, X., Liu, C., Chen, J., Chen, L., Ren, X., Hou, M., Cui, X., Jiang, Y., Liu, E., Zong, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00445-8 · Cited by 79
Prendergast, Á. M., Cruet-Hennequart, S., Shaw, G., Barry, F., & Carty, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.21.17972 · Cited by 79
COL10A1 Expression is Elevated in Diverse Solid Tumor Types and is Associated with Tumor Vasculature
Chapman, K. B., Prendes, M. J., Sternberg, H., Kidd, J. L., Funk, W. D., Wagner, J., & West, M. D. (2012) · Future Oncology · doi:10.2217/fon.12.79 · Cited by 79
“Functionally consistent with this model is the observation that bone marrow-derived MSCs, when mixed with human breast carcinoma cells, enhance the metastatic potential of the resulting tumor when the cell mixture is injected subcutaneously [22].”
Background
Metadata
- Authors
- Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Weinberg, Robert A.
- Venue
- Nature
- Published
- 2007-10-04
- Volume
- 449
- Issue
- 7162
- Pages
- 557-563
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2141815918
- Cited by
- 3,206
- References
- 36
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 95 · 2023: 137 · 2022: 144 · 2021: 186 · 2020: 192 · 2019: 153 · 2018: 145 · 2017: 176 · 2016: 182 · 2015: 222 · 2014: 232 · 2013: 232 · 2012: 216
- FWCI
- 89.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P50CA089393, R01CA116235)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- mesenchymal stem cells, breast cancer metastasis, tumor stroma, RANTES, CCR5, paracrine signaling, tumor cell motility, tumor invasion, tumor microenvironment, bone marrow-derived stem cells, tumor xenografts
- MeSH terms
- Animals, Breast Neoplasms, Cell Movement, Fibroblasts, Humans, Lung Neoplasms, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Mice, SCID, Mice, Inbred NOD, Stromal Cells, Carcinoma, Ductal, Breast, Chemokine CCL5, Receptors, CCR5, Chemokines, CC, Paracrine Communication, Mesenchymal Stem Cell Transplantation, Cell Line, Tumor, Mice, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.